Kite Pharma appoints Chris Nowers as head of Europe to lead commercial operations

13 October 2016

US cancer drug developer Kite Pharma’s (Nasdaq: KITE) today announced the appointment of Chris Nowers as its head of Europe. He will be based in London.

In his new role, Mr Nowers will oversee European commercial operations to build awareness in the region of Kite’s growing pipeline portfolio of chimeric antigen receptor (CAR) and T-cell receptor (TCR) therapy product candidates and prepare for the potential launch of the company’s lead product candidate, KTE-C19.

“The addition of Chris Nowers to our executive team will be instrumental to Kite as we expand our global footprint,” said Arie Belldegrun, chairman, president and chief executive of Kite. “The breadth of Chris’ commercial experience in global immuno-oncology is impressive, and makes him well-qualified to propel our pipeline of CAR-T and TCR therapy candidates to treat both blood-based and solid cancers into international markets,” Dr Belldegrun added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK